Funder: Novartis

The Panorama Heart Failure Clinical Study is an industry-sponsored clinical trial of heart failure medication in a paediatric population. It comprises a multicentre, open-label, study to evaluate the safety, tolerability, pharmacokinetics and, pharmacodynamics of LCZ696 followed by a 52-week randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared with enalapril in paediatric patients from 1 month to < 18 years of age with heart failure due to systemic left ventricle systolic dysfunction.